Toward a reliable distinction between patients with mild cognitive impairment and Alzheimer-type dementia versus major depression

被引：25

作者：

Post, A ^{[1
]}

Ackl, N ^{[1
]}

Rücker, M ^{[1
]}

Schreiber, Y ^{[1
]}

Binder, EB ^{[1
]}

Ising, M ^{[1
]}

Sonntag, A ^{[1
]}

Holsboer, F ^{[1
]}

Almeida, OFX ^{[1
]}

机构：

[1] Max Planck Inst Psychiat, D-80804 Munich, Germany

来源：

BIOLOGICAL PSYCHIATRY | 2006年 / 59卷 / 09期

关键词：

sAPP; alpha-sAPP; mild cognitive impairment; Alzheimer disease; CSF; major depression;

D O I：

10.1016/j.biopsych.2005.09.007

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Background: Cerebrospinalfluid (CSF) levels of soluble amyloid precursor protein (sAPP) and its alpha-secreted form (alpha-sAPP) were investigated as a means to distinguish between individuals with mild cognitive impairment(MCI) and Alzheimer-type dementia (DAT) and those with major depressive episode (4/01.) showing secondary memory deficits. Methods: Twenty-seven patients with MCI, 32 with probable DAT and 24 with MDE attending a memory clinic were studied. Cerebrospinalfluid levels of sAPP/amyloid precursor-like protein 2 (APLP2) and alpha-sAPP were detected by Western blotting. Results: Patients with MDE bad the highest CSF levels of total sAPP/APLP2 as compared With MCI and DAT patients (p <.001); sAPP/APLP2 levels were higher in MCI than in DAT subjects. Whereas alpha-sAPP levels did not differ between the the MCI and DAT groups, median levels of this peptide were significantly lower in MCI and DAT versus MDE patients. Conclusions: Soluble amyloid precursor protein/APLP2 and alpha-sAPP concentrations in CSF can differentiate between DAT and MCI versus MDE, facilitating early ameliorative interventions and appropriate treatment regimens.

引用

页码：858 / 862

页数：5

共 31 条

[1] Cerebrospinal fluid levels of alpha-secretase-cleaved soluble amyloid precursor protein mirror cognition in a Swedish family with Alzheimer disease and a gene mutation [J].